Biolegend, 506510, APC anti-human IFN-γ Antibody
100tests
Catalog Number: 506510
Send an RFQ.
Category
| Verified Reactivity | Human |
|---|---|
| Reported Reactivity | Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Immunogen | E. coli-expressed recombinant human IFN-γ |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA) |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. |
| Storage & Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | ICFC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. |
| Excitation Laser | Red Laser (633 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Flow Cytometry2: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-? -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.Neutralization1,3,6,7: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IFN-? bioactivity (Cat. No. 506531). |
| Application References(PubMed link indicates BioLegend citation) | Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut) Kaur A, et al. 2002. J Virol. 76:3646. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. Rout N, et al. 2010. PLoS One 5:e9787. (FC) Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut) Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut) |
|---|
| Product Citations | Yang Y, et al. 2023. MBio. 14:e0328522. PubMed Saeland E, et al. 2023. NPJ Vaccines. 8:45. PubMed Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed Han Z, et al. 2022. J Invest Dermatol. 142:603. PubMed Yen M, et al. 2022. Cell. 185:1414. PubMed Laurent A, et al. 2014. PLoS One. 9:103683. PubMed Nesterenko PA, et al. 2021. Cell Rep. 37:110167. PubMed Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed Marques RM, et al. 2021. Cell Death Differ. 28:3140. PubMed Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed Shi Z, et al. 2021. Ann Clin Transl Neurol. 8:43. PubMed Blandine Monel et al. 2019. Cell reports. 27(1):142-153 . PubMed Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed Juno JA, et al. 2020. Nat Med. 26:1428. PubMed Rölle A, et al. 2018. Cell Rep. 24:1967. PubMed Torres-Ruiz J, et al. 2021. Front Immunol. 12:689966. PubMed Alrubayyi A, et al. 2021. Nat Commun. 12:5839. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed Zhuang X, et al. 2019. Cancer Immunol Res. 0.94375. PubMed Johnson JK, et al. 2022. Methods Mol Biol. 2470:641. PubMed Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed Matsuzawa T, et al. 2017. J Dermatol Sci. 10.1016/j.jdermsci.2017.03.015. PubMed Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed Qiu X, et al. 2013. Sci Transl Med. 16:207. PubMed Robert R, et al. 2017. PLoS One. 10.1371/journal.pone.0184278. PubMed Min HK, et al. 2021. Immune Netw. 21:e43. PubMed Marzan-Rivera N, et al. 2022. iScience. 25:104764. PubMed Lee IK, et al. 2020. Cancers (Basel). 12:. PubMed Nesterenko PA, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed |
|---|
| RRID | AB_315443 (BioLegend Cat. No. 506510) |
|---|
| Structure | Cytokine; dimer; 20-25 kD (Mammalian) |
|---|
| Bioactivity | Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC |
|---|
| Cell Sources | CD8+ and CD4+ T cells, NK cells |
|---|
| Cell Targets | T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts |
|---|
| Receptors | IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1) |
|---|
| Cell Type | Tregs |
|---|
| Biology Area | Cell Biology, Immunology, Neuroinflammation, Neuroscience |
|---|
| Molecular Family | Cytokines/Chemokines |
|---|
| Antigen References | 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151. |
|---|
| Regulation | Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2 |
|---|
| Gene ID | 3458 |
|---|
| UniProt | View information about IFN-gamma on UniProt.org |
|---|
| Clone | B27 |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma |
|---|
| Isotype | Mouse IgG1, κ |
|---|